Bressler SB, et al. - Among eyes with diabetic macular edema treated with ranibizumab, researchers assessed the 5-year changes in diabetic retinopathy severity from baseline. Improvement percentages among 111 participants with proliferative diabetic retinopathy were 38%, 35%, and 23% at 1, 3, and 5 years, and among 235 participants with nonproliferative diabetic retinopathy at baseline, they were 29%, 28%, and 32% for the respective time points. Favorable changes in diabetic retinopathy severity throughout a 5-year period concomitant with sequential reduction in anti–vascular endothelial growth factor therapy could be found in individuals receiving ranibizumab therapy for diabetic macular edema.